ERBB3 and thyroid gland carcinoma: Montero-Conde et al. reported that thyroid cancer with the BRAF mutation overexpressed human epidermal growth factor receptor 3 (HER3) via autocrine-secreted NRG1 secretion when treated with BRAF inhibitor.